NCT01435460

Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)

A Clinical Safety and Efficacy Evaluation of Alrex® (Loteprednol Etabonate Ophthalmic Suspension, 0.2%) Versus Patanol (Olopatadine Hydrochloride Ophthalmic Solution, 0.1%) in the Treatment of Seasonal Allergic Conjunctivitis (SAC)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 300 (actual)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal Allergic Conjunctivitis (SAC).

Conditions

• Seasonal Allergic Conjunctivitis

Interventions

Type	Name	Description
DRUG	Loteprednol etabonate 0.2%	1 drop of Alrex 4 times daily (QID) in both eyes at approximately 4 hour intervals for 2 weeks.
DRUG	Olopatadine 0.1%	1 drop of Patanol 2 times daily (BID)at intervals of 6-8 hours or more for 2 weeks.

Timeline

• Start date: 2010-08-01
• Primary completion: 2011-04-01
• Completion: 2011-05-01
• First posted: 2011-09-16
• Last updated: 2012-03-13
• Results posted: 2012-03-13

Locations

1 site across 1 country: Singapore